Get the Stockscreener App
14.79
5.12%
0.72
After Hours:
14.86
0.07
+0.47%
Moonlake Immunotherapeutics stock is traded at $14.79, with a volume of 2.36M.
It is up +5.12% in the last 24 hours and up +15.82% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$14.07
Open:
$14.24
24h Volume:
2.36M
Relative Volume:
0.48
Market Cap:
$1.05B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-6.4304
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-0.74%
1M Performance:
+15.82%
6M Performance:
-66.40%
1Y Performance:
-72.49%
1-Day Range:
$14.10
$14.98
1-Week Range:
$13.87
$15.55
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
14.79 | 996.82M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6%Still a Buy? - MarketBeat
Phase 3 Miss and Fraud Suits Could Be A Game Changer For MoonLake Immunotherapeutics (MLTX) - simplywall.st
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms - GlobeNewswire Inc.
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - marketscreener.com
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action LawsuitHagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms - PR Newswire
MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025MLTX - PR Newswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Have MoonLake Immunotherapeutics Insiders Been Selling Stock? - simplywall.st
MLTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics ... - Caledonian Record
Kristian Reich Sells 130,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
Investors who lost money on MoonLake Immunotherapeutics - GlobeNewswire
MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – - The National Law Review
MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025MLTX - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Top Executives Cash In on MoonLake Immunotherapeutics Stock! - TipRanks
MoonLake Immunotherapeutics(MLTX.US) Officer Sells US$3.01 Million in Common Stock - 富途牛牛
MOONLAKE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Understanding the Setup: (MLTX) and Scalable Risk - news.stocktradersdaily.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
Ready to Jump After Recent Trade: MoonLake Immunotherapeutics (MLTX) - setenews.com
MLTX NOTIFICATION: BFA Law Notifies MoonLake Immunotherapeutics Investors of the Pending Class Action Lawsuit and Upcoming December 15 Legal Deadline - TMX Newsfile
MLTX DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
MLTX 6-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Fa - GuruFocus
MLTX 6-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of MoonLake Immunotherapeutics, Inc. Investors - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations - ACCESS Newswire
Marshall Wace LLP Sells 111,706 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - ACCESS Newswire
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash - AOL.com
MLTX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
MLTX 1-WEEK DEADLINE ALERT: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
Contact The Gross Law Firm by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX) - Sahm
2025-12-07 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX INVESTOR LOSSES: Lose Money on MoonLake - GlobeNewswire
MLTX 9-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MLTX SECURITIES ALERT: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses of Important December 15 Securities Class Action Deadline - marketscreener.com
Are MoonLake (MLTX) Securities Lawsuits Quietly Reframing the Credibility of Its Drug Innovation Story? - simplywall.st
MLTX IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, - GlobeNewswire
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Se - GuruFocus
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):